Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | MMP3 | P08254 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP14 | P50281 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8919391 | 0.85 | NAALAD2 (0.46) | NAALAD2ALDH1A1CYP1A2LMNAPOLB | |
| SCHEMBL12463081 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CYP1A2LMNAPOLBMEN1 | |
| SCHEMBL21142858 | 0.83 | LMNA (0.51) | ALDH1A1CYP1A2LMNAPOLBMEN1 | |
| SCHEMBL5743537 | 0.83 | LMNA (0.51) | ALDH1A1CYP1A2LMNAPOLBMEN1 | |
| SCHEMBL13545121 | 0.83 | MTNR1A (0.46) | ALDH1A1CYP1A2LMNAPOLBMEN1 | |
| SCHEMBL303413 | 0.82 | FPR2 (0.57) | NAALAD2ALDH1A1LMNAKMT2AFPR2 | |
| SCHEMBL28295320 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A2LMNAPOLBMEN1 | |
| SCHEMBL633778 | 0.82 | FPR2 (0.57) | NAALAD2ALDH1A1LMNAKMT2AFPR2 | |
| SCHEMBL890110 | 0.81 | TACR3 (0.45) | NAALAD2ALDH1A1LMNAKMT2ASLC6A3 | |
| SCHEMBL8915495 | 0.80 | CYP2C19 (0.52) | ALDH1A1CYP1A2LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | NAALAD2 2518/4885ALDH1A1 365/4885CYP1A2 205/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | NAALAD2 1627/4885ALDH1A1 229/4885CYP1A2 240/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | NAALAD2 1989/4885ALDH1A1 287/4885CYP1A2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.